Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02767804 · ClinicalTrials.gov registry record · Phase 3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Xcovery Holdings.
- Active
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT02767804 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Xcovery Holdings. The registered enrollment target is 290 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02767804, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Xcovery Holdings.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
Conditions Studied
Interventions
- DRUG X-396 (ensartinib)
- DRUG crizotinib
Study Locations (20)
Other
- Sanatorio Parque S.A. - Rosario
- Chris O Brien Lifehouse - Camperdown
- Catholic University of Louvain (UCL) - Site Mont Godinne - Yvoir
- Hospital Haroldo Juaçaba - Instituto do Cancêr do Ceará - Fortaleza
- Fundacao do ABC Faculdade de Medicina do ABC - São Paulo
Beijing Municipality
- Beijing Chao Yang Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
- Peking University Cancer Hospital - Beijing
- Beijing Chest Hospital,Capital Medical University - Beijing
New South Wales
- Border Medical Oncology Research Unit - Albury
- Chris O'Brien Lifehouse - Camperdown
São Paulo
- Instituto do Câncer do Estado de São Paulo - São Paulo
- Hospital de Câncer de Barretos - Fundação Pio XII - São Paulo
Florida
- Moffitt Cancer Center - Tampa
Georgia
- University Cancer & Blood Center - Athens
Missouri
- Washington University School of Medicine - St Louis
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2016-06 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02767804
The ClinicalTrials.gov registry entry for NCT02767804 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (56% lower). The listed sponsor is Xcovery Holdings, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which X-396 (ensartinib) is the first listed.
NCT02767804 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Beijing Municipality, New South Wales.
Frequently Asked Questions
What is clinical trial NCT02767804 about?
NCT02767804 is a clinical study titled "eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients". The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
What is the current status of trial NCT02767804?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2016-06. Estimated completion is 2025-12-31.
What conditions does trial NCT02767804 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02767804?
The interventions under investigation include: X-396 (ensartinib) (DRUG), crizotinib (DRUG).
Who is sponsoring clinical trial NCT02767804?
This trial is sponsored by Xcovery Holdings, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02767804 being conducted?
This trial has 20 study locations across Florida, Georgia, Missouri, Oregon, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.